Ascentage Pharma Group International – Unsponsored ADR (NASDAQ:AAPG) Receives $46.43 Average PT from Analysts

Ascentage Pharma Group International – Unsponsored ADR (NASDAQ:AAPG) has earned an average rating of “Buy” from the ten research firms that are currently covering the firm, Marketbeat reports. Eight research analysts have rated the stock with a buy recommendation and two have assigned a strong buy recommendation to the company. The average 1-year price objective among analysts that have updated their coverage on the stock in the last year is $46.4286.

AAPG has been the subject of several recent analyst reports. Raymond James Financial reaffirmed a “buy” rating on shares of Ascentage Pharma Group International in a report on Wednesday, June 10th. China Intl Cap raised shares of Ascentage Pharma Group International to a “strong-buy” rating in a report on Monday, April 6th. B. Riley Financial initiated coverage on shares of Ascentage Pharma Group International in a report on Wednesday, June 10th. They set a “buy” rating and a $45.00 price objective for the company. Deutsche Bank Aktiengesellschaft initiated coverage on shares of Ascentage Pharma Group International in a report on Friday, April 24th. They set a “buy” rating and a $40.00 price objective for the company. Finally, BTIG Research reaffirmed a “buy” rating and set a $48.00 price objective on shares of Ascentage Pharma Group International in a report on Monday.

Institutional Trading of Ascentage Pharma Group International

Several large investors have recently modified their holdings of the company. Citadel Advisors LLC bought a new stake in shares of Ascentage Pharma Group International in the third quarter valued at approximately $383,000. Hsbc Holdings PLC bought a new stake in shares of Ascentage Pharma Group International in the second quarter valued at approximately $391,000. XY Capital Ltd boosted its position in shares of Ascentage Pharma Group International by 224.2% in the third quarter. XY Capital Ltd now owns 18,120 shares of the company’s stock valued at $707,000 after acquiring an additional 12,530 shares during the period. Finally, UBS Group AG boosted its position in shares of Ascentage Pharma Group International by 149.4% in the third quarter. UBS Group AG now owns 18,345 shares of the company’s stock valued at $716,000 after acquiring an additional 10,988 shares during the period.

Ascentage Pharma Group International Price Performance

Shares of NASDAQ:AAPG opened at $17.09 on Friday. Ascentage Pharma Group International has a 1 year low of $16.92 and a 1 year high of $48.45. The firm has a fifty day moving average price of $21.48 and a 200 day moving average price of $24.38. The company has a current ratio of 1.79, a quick ratio of 1.77 and a debt-to-equity ratio of 0.57.

Ascentage Pharma Group International (NASDAQ:AAPG) last issued its quarterly earnings data on Wednesday, March 25th. The company reported ($0.52) earnings per share (EPS) for the quarter. The company had revenue of $24.72 million for the quarter. On average, equities analysts expect that Ascentage Pharma Group International will post -0.96 earnings per share for the current fiscal year.

About Ascentage Pharma Group International

Ascentage Pharma Group International is a clinical‐stage biopharmaceutical company focused on developing small‐molecule therapeutics that modulate programmed cell death pathways, including the Bcl‐2 family and the MDM2–p53 axis. Its pipeline features orally bioavailable inhibitors such as APG-2575, a selective Bcl-2 inhibitor, and APG-115, a potent MDM2 antagonist, both aimed at reactivating apoptosis in cancer cells across hematologic malignancies and solid tumors.

Founded in 2008 by biotechnology entrepreneur Dr.